These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 1899681

  • 1. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator.
    Mehta JL, Nicolini FA, Nichols WW, Saldeen TG.
    J Am Coll Cardiol; 1991 Mar 01; 17(3):805-11. PubMed ID: 1899681
    [Abstract] [Full Text] [Related]

  • 2. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 01; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 3. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar 01; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

  • 4. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY, Nichols WW, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1996 Feb 01; 27(2):283-9. PubMed ID: 8720429
    [Abstract] [Full Text] [Related]

  • 5. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW, Nicolini FA, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1991 Aug 01; 18(2):231-6. PubMed ID: 1717784
    [Abstract] [Full Text] [Related]

  • 6. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL, ter Riet MF.
    J Cardiovasc Pharmacol; 1990 Jul 01; 16(1):112-20. PubMed ID: 1696653
    [Abstract] [Full Text] [Related]

  • 7. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul 01; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 8. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb 01; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan 01; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 10. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
    Nicolini FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C.
    J Am Coll Cardiol; 1992 Jul 01; 20(1):228-35. PubMed ID: 1607530
    [Abstract] [Full Text] [Related]

  • 11. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengård C, Hedner U, Saldeen TG.
    J Am Coll Cardiol; 1995 Mar 01; 25(3):753-60. PubMed ID: 7860925
    [Abstract] [Full Text] [Related]

  • 12. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Dec 01; 16(7):1728-35. PubMed ID: 2123910
    [Abstract] [Full Text] [Related]

  • 13. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, Lucchesi BR.
    Eur J Pharmacol; 1999 Jun 25; 374(3):399-410. PubMed ID: 10422784
    [Abstract] [Full Text] [Related]

  • 14. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T, Saitoh S, Asakura T, Kanke M, Owada K, Maruyama Y.
    Int J Cardiol; 1993 Mar 25; 38(3):225-33. PubMed ID: 8463004
    [Abstract] [Full Text] [Related]

  • 15. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 25; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 16. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 25; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 17. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 25; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 18. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 25; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 19. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 25; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 20. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr 25; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.